Preliminary results are promising across all tumor types and correlate with HER2 expression with an ORR of 37.1% for all participants and 45% in the ovarian cohort (abstract LBA3000, abstract LBA34).14,15 It is unknown if clear cell carcinoma was represented in this trial as the ovarian cancer subtypes were not reported. Here, ERBB2 is linked to neoplasm.